# Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer

> **NCT00040365** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Amifostine trihydrate
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT00040365
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2010-05
- **Final completion:** 2011-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040365, "Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00040365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*